SPACE CHEMISTRY AND GLOBAL HEALTH: DRUG DEVELOPMENT AGAINST COVID-19 IN SPACE

Gergo Mezohegyi Balázs Buchholcz Tamás Sohajda István Puskás Lajos Szente Ferenc Darvas

UNOOSA Technical presentation for the 58th Scientific and Technical Subcommittee 23 April 2021



Global health issues to be solved - in space


- Performing drug discovery and chemistry in space offers a huge opportunity for developing health of human mankind
- Novel APIs (active pharmaceutical ingredients) development: here microgravity can ensure faster, more efficient reaction routes, even novel reaction products which are difficult to synthesize on earth. API production in space: needed also by long-term space traveling
- Large number of other important chemical applications, e.g. CO₂ transformation into valuable materials, like plastics, on-site propellant production on space objects....
- Effects in space: microgravity, low temperature, radiation, unknown effects

Jones, R.; Darvas, F. & Janáky, Cs. (2017), *Nature Rev. Chem.*, 1, Article number: 0055 Braddock, M. (2020), *Curr. Drug Discov. Technol.*, 17(1), 45-56.




Remdesivir, the targets of our experiments on ISS

- One of the most important and most widely used drug against COVID-19
- Marketed as Veklury[®], in form of a cyclodextrin complex. It is the very first approved anti-COVID drug
- Has serious limiting factors in its application, like it accumulates in patients with decreased renal function. It cannot be used in a wide group of COVID patients



- An improvement of the REM/cyclodextrin (R/C) ratio would allow in increasing the treateable client group. Unfortunately, increase of R/C could not yet been achieved > research in space justified
- It is the first time that an anti-COVID research went to space
- It is the first time that effect on a drug-cyclodextrin complex was studied in the space
- <u>Our venture created a world-wide interest</u>: https://finance.yahoo.com/news/innostudio-launchesconsortium-developing-coronavirus-144909829.html

Going to ISS and returning to Earth




After return from space: processing of samples

Complex instrumental analysis, including:

- Rapid visual comparison of samples by optical microscopy
- Determination of particle size distribution by Field Emission Scanning Electron Microscopy (FE-SEM)
- REM crystal structures by X-ray Powder Diffraction (XRD)
- Analysis of REM polymorphy and crystallinity by Raman Spectroscopy
- Determination of dissolved REM by HPLC (from supernatant)
- Detection of contingent degradation products of REM and SBECD by HPLC fingerprint (from supernatant)
- Chemometrical evaluation of the instrumental results is still ongoing

Morphological Investigation: FE-SEM




Visible and statistical differences among reference (G) and space (S) samples

Chromatography (HPLC) – unexpected results

Sample	рН	REM (mg/ml)	REM _{AV} (mg/ml)	SD (mg/ml)	REM/SBECD (w%)
G1_1	7.0	0.97	1.02	0.04	0.5
G1_2		1.04			
G1_3		1.04			
G2_1	3.5	5.65	5.66	0.01	2.8
G2_2		5.65			
G2_3		5.66			
S1_1	7.0	0.97	1.01	0.04	0.5
S1_2		1.05			
S1_3		1.01			
S2_2	3.5	5.48	5.47	0.01	2.7
S2_3		5.46			
S2_4		5.45			

- REM (at pH neutral) in space and reference samples degraded unproportionally and in different manner;
- Stability for one REM sample in space increased, relative to reference.
- This is an unexpected and important result.
- No demonstrable product with higher REM/cyclodextrin ratio.
- Cyclodextrin was not degraded in either samples.



Main results so far - Ongoing efforts

REM stability unexpectedly increased in space for samples with neutral pH. <u>This result may have clinical significance</u>. Decomposition routes modelling by computer will follow. Decomposition mechanism may differ in space.

Complex formation with cyclodextrin might occur via an altered mechanism. Continuation: Complex formation modelling by computer.

Received morphologically different, and, by decomposition, chemically modified samples in space - **Experimental IC50** evaluation is the logical next step against living SARS-CoV-2 virus. This result may have clinical significance.

8

No success in preparing a remdesivir-cyclodextrin complex with higher REM ratio.


Any collaborative idea? Clinical capacity? Please contact us.

Results of this study are protected by submitted patent applications.



Still worths mentioning: integrated standardization efforts

No appropriate standards encompassing the entire procedure



About InnoStudio, Inc.

- One of the world leaders in space chemistry
- Established in 2005, member of one of the largest upstream technology networks (ThalesNano/Darholding) in Central Europe, in Budapest
- Substantial discovery related results on ISS (nanoformulation, co-crystal formulation, protein crystallization, besides present remdesivir project), all related to improvement of global health
- Design & development of flow synthesis instruments for space research together with holding members ThalesNano, Inc. and ThalesNano Energy, Inc.
- Teaming in anti-COVID research also with ComInnex, Inc., an another holding member
- Teaming in CO₂ conversion to polymers in space with **ThalesNano Energy**
- Promotes self-organization of the Space Chemistry Community: organizing consortiums, symposiums (6), publication forums





About CycloLab Ltd. (Budapest)

- The world's only all-round cyclodextrin company with over 40-year experience of cyclodextrin technology
- Pioneer in cyclodextrin technology hosting the first International Cyclodextrin Symposium in 1981 (since then, the Symposium has been organized 19 times)
- Main fields of expertise: pharmaceutical-, cosmetics, food-, environmental- and analytical applications
- Producer of 200 different cyclodextrin derivatives, amongst which betadex sulfobutyl ether sodium (SBECD) is produced in multiple ton scale per annum under GMP conditions in parenteral grade
- Over 490 peer reviewed scientific papers in cyclodextrin field, with over 20.000 citations



Thank you for your attention!

Special thanks for contribution Sz. Gilmore (INS), P.Kormos (THS), R.Jones (THSE), E.Szilágyi (CLB), G.Tóth (CLB), G.Benkovics (CLB), Z.Kónya (SZTE) György Dormán, CIX N.Sato (JAMSS), H.Stenuit (SAA)

<u>gergo.mezohegyi@innostudio.org</u> <u>ferenc.darvas@innostudio.org</u>



